I-Cabazitaxel iyisidakamizwa esisetshenziselwa ukwelapha umdlavuza, okuyingxenye yezidakamizwa ezibizwa ngokuthi “i-paclitaxel analogues”. Le mithi ingavimbela ukukhula nokwehlukana kwamangqamuzana esimila, ngaleyo ndlela yehlise noma ivimbele ukuqhubeka komdlavuza.
I-Cabazitaxel yatholwa okokuqala ngososayensi e-National Cancer Institute e-United States.Ngemva kweminyaka yocwaningo nentuthuko, i-cabazitaxel isiphenduke isidakamizwa esilwa nomdlavuza esetshenziswa kakhulu emitholampilo.Ingasetshenziswa ukwelapha izinhlobo eziningi zomdlavuza, okuhlanganisa nomdlavuza webele, umdlavuza wesibeletho, umdlavuza wamaphaphu ongewona omncane, umdlavuza wendlala yesinye, umdlavuza wesisu, umdlavuza wamaphaphu, njll.
Umgomo wokwelapha wei-cabazitaxelukuvimbela ukukhula nokwanda kwamangqamuzana e-tumor ngokuphazamisa inqubo yawo ye-Mitosis. Ngokukhethekile, i-cabazitaxel ingahlangana ne-Tubulin ukuze kuvinjelwe i-polymerization kanye ne-depolymerization ye-Tubulin, ngaleyo ndlela kuthinte inqubo ye-Mitosis yamangqamuzana e-tumor, okuholela ekutheni amaseli angakwazi ukuhlukana. futhi zande ngokujwayelekile, futhi ekugcineni ziholele ekufeni kweseli lesimila.
I-Cabazitaxeliyisidakamizwa esibalulekile sokulwa nomdlavuza esinikeza ithemba namathuba ezigulini eziningi zokwelapha umdlavuza.Ngenqubekelaphambili eqhubekayo yesayensi nobuchwepheshe, kukholakala ukuthi ukusebenza kahle nokuphepha kwe-cabazitaxel kuzothuthukiswa nakakhulu.
Ukufundwa okunwetshiwe:I-Hande Biotech ibigxile ekukhiqizweni kwe-paclitaxel iminyaka eminingi, futhi iyibhizinisi elizimele lokukhiqiza le-paclitaxel izinto zokusetshenziswa zemithi elwa nomdlavuza ekhishwa isitshalo egunyazwe izinhlangano ezilawula izwe njenge-US FDA, European EDQM, Australian TGA, China. I-CFDA, i-India, i-Japan, njll.I-Yunnan Hande inikeza ikhwalithi ephezuluI-Cabazitaxelizinto zokusetshenziswa, ezitholakala esitokweni.Uma uzidinga, sicela ukhululeke ukusithinta nganoma yisiphi isikhathi.
Isikhathi sokuthumela: Jun-08-2023